Cancer Immunotherapy with Liposomal Antigen Delivery Systems
Summary
Cancer immunotherapy harnesses the body’s immune defences to recognise and eliminate malignant cells. Liposomal antigen delivery systems encapsulate tumour-associated antigens or immunomodulatory agents within lipid bilayer vesicles, enhancing stability, circulation time and targeted uptake by key immune cells. By decorating vesicle surfaces with ligands or antibodies, these systems direct delivery to dendritic cells, regulatory T cells or components of the tumour microenvironment, promoting efficient antigen cross-presentation via MHC class I pathways and robust CD8+ T-cell activation. Advances include stimulus-responsive formulations that release cargo under acidic or enzymatic triggers, lipid nanoparticles for nucleic acid vaccines and immunoliposomes combining checkpoint inhibitors with chemotherapeutics. Such technologies address challenges of off-target toxicity, poor tumour penetration and immunosuppressive niches, and have shown promising preclinical efficacy across solid tumours and haematological malignancies.
Research from Nature Portfolio
Foundational studies have demonstrated that cationic liposomes loaded with recombinant protein antigens and adjuvants are taken up efficiently by dendritic cells through pinocytosis. Once internalised, antigens enter endosomal routes that favour cross-presentation on MHC class I molecules, eliciting strong CD8+ T-cell responses. Detailed mechanistic work showed that lipid unsaturation and vesicle composition critically influence intracellular trafficking and immune activation, laying the groundwork for safe subunit vaccine strategies against intracellular pathogens and tumours.
Cancer Immunotherapy with Liposomal Antigen Delivery Systems publication trend
The graph below shows the total number of articles in cancer immunotherapy with liposomal antigen delivery systems across all publications each year (not limited to Nature Index journals).
Technical terms
Liposomes: Spherical vesicles composed of phospholipid bilayers, used to encapsulate hydrophilic or lipophilic therapeutic agents for targeted delivery.
Antigen-presenting cells: Immune cells such as dendritic cells and macrophages that process and display antigenic peptides on MHC molecules for T-cell recognition.
Major histocompatibility complex (MHC) class I pathway: The intracellular route by which endogenously derived peptides are presented on cell surfaces to CD8+ T cells.
Immunoliposomes: Liposomes functionalised with targeting ligands or antibodies to direct encapsulated cargo to specific cell types.
Tumour microenvironment: The local ecosystem surrounding a tumour, including immune cells, stromal cells and extracellular matrix, which influences therapeutic response.
References
- Lipid-based nanosystems: the next generation of cancer immune therapy. Journal of Hematology & Oncology (2024).
- Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy. Military Medical Research (2023).
- Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers. Cell Death & Disease (2024).
- Liposome-Coupled Antigens Are Internalized by Antigen-Presenting Cells via Pinocytosis and Cross-Presented to CD8+ T Cells. PLOS ONE (2010).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.